Compare EMA & MEDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EMA | MEDP |
|---|---|---|
| Founded | 1998 | 1992 |
| Country | Canada | United States |
| Employees | 7812 | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.8B | 12.9B |
| IPO Year | N/A | 2016 |
| Metric | EMA | MEDP |
|---|---|---|
| Price | $53.23 | $456.36 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 13 |
| Target Price | N/A | ★ $498.25 |
| AVG Volume (30 Days) | 231.2K | ★ 310.4K |
| Earning Date | 05-07-2026 | 04-20-2026 |
| Dividend Yield | ★ 3.97% | N/A |
| EPS Growth | N/A | ★ 20.98 |
| EPS | N/A | ★ 15.28 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $13.11 |
| Revenue Next Year | $11.18 | $7.51 |
| P/E Ratio | ★ $19.19 | $29.90 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $43.90 | $250.05 |
| 52 Week High | $53.91 | $628.92 |
| Indicator | EMA | MEDP |
|---|---|---|
| Relative Strength Index (RSI) | 64.98 | 42.26 |
| Support Level | $47.18 | $418.96 |
| Resistance Level | N/A | $477.04 |
| Average True Range (ATR) | 0.77 | 16.42 |
| MACD | 0.08 | 3.70 |
| Stochastic Oscillator | 80.34 | 43.32 |
Emera is a geographically diverse energy and services company investing in electricity generation, transmission, and distribution as well as gas transmission and utility energy services. Emera has operations throughout North America and the Caribbean countries.
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms. It also offers ancillary services, including bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has more than 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are primarily based in the US, with additional presence in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.